Cognitive Effects of Bioavailable Curcumin (NCT07251985) | Clinical Trial Compass
WithdrawnPhase 2
Cognitive Effects of Bioavailable Curcumin
Stopped: Sponsor withdrew.
0Started 2026-04-01
Plain-language summary
An estimated 50% of older adults complain of memory changes that worsen as they age. Although numerous commercially available dietary supplements claim cognitive benefits, relatively few well-designed, longitudinal, placebo-controlled studies have rigorously evaluated their effects on cognitive performance.
In a previous double-blind, randomized, placebo-controlled, 18-month clinical trial in middle-aged and older non-demented adults, the investigators found that a bioavailable form of curcumin taken orally twice a day showed greater gains on specific measures of memory and attention relative to placebo. Although the investigators found significant between-group curcumin/placebo differences with moderate effect sizes, the sample size (n=40) was small. The present adequately powered, randomized, double-blind, placebo-controlled study will evaluate the effect of daily consumption of bioavailable curcumin on measurable changes in cognitive performance in non-demented middle-aged and older adults.
Who can participate
Age range
50 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Presence of age-related memory complaints;
. Male or female aged 50 to 85 years of age at Visit 1.
. performance on MoCA test of \>= 18 (Milani et al, 2018)
. Ability to perform normal daily activities independently (which excludes a diagnosis of dementia).
. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
. Agreement to participate in the entire study, which could last either 6 or 12 months depending on results of the interim analysis.
. Adequate visual and auditory acuity for cognitive testing.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Screening laboratory tests that do not show significant medical problems that might interfere with study participation or impact cognitive test results.
Exclusion criteria
. Allergy to curcumin
. Presence of a condition or abnormality that in the opinion of the site Principal Investigator would compromise the safety of the patient or the quality of the data.
. Significant cerebrovascular disease or Alzheimer disease or any other dementia.
. Neurological or physical illnesses that can produce cognitive deterioration.
. History of myocardial infarction within the previous year or unstable cardiac disease.
. Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100); significant liver or pulmonary disease, or cancer;
. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria with a change in medication or clinical symptoms with the last 3 months prior to screening (APA, 2000).
. History of alcoholism or substance addiction in the last 15 years.